1. Scrip

Bayer Hot On The Trail Of Astellas As Menopause Drug Flies In Phase III

 
• By Kevin Grogan

Astellas’s fezolinetant is already on the market but Bayer is confident its non-hormonal menopause drug elinzanetant will be able to catch up on the back of demonstrating significant reductions in the frequency and severity of hot flashes in a couple of Phase III trials.

Bayer cross
• Source: Bayer

Astellas Pharma, Inc. is currently ahead in the non-hormonal menopausal relief race but Bayer AG is coming up on the rails after reporting positive results from two late-stage trials for elinzanetant.

Key Takeaways
  • Menopause drug elinzanetant hits four primary endpoints in two studies
  • Still has a lot of ground to make up on rival fezolinetant from Astellas
  • Boost

The German group has released topline data from the OASIS 1 and 2 Phase III studies evaluating elinzanetant, the non-hormonal menopause drug for vasomotor symptoms (VMS) such as hot flashes and night sweats that came with Bayer's September 2020 acquisition of the UK's KaNDy Therapeutics Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Women's Health

More from Scrip

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.